Ipsen: David Loew, CEO
Pharmaceutical firm Ipsen has appointed David Loew CEO and new board member, effective July 1. His mission will be to ensure the company’s growth and advance its products through innovation.
Loew had been CEO of Sanofi Pasteur Vaccines since 2016. He brings to the company nearly three decades across a range of therapeutic areas (including oncology, CNS and cardio-metabolism), as well as consumer healthcare. He has worked for a number of companies in the US, European and international markets, including Roche and Hewlett Packard.
Marc De Garidel, chairman of Ipsen, said, “I have full confidence that David will provide the leadership and expertise needed to guide the group through its next phase of growth and realize Ipsen’s vision of being a global biotechnology leader through the identification, development and commercialization of transformative and differentiated products.”